Sanofi and Regeneron announced the European Commission approved Dupixent for treating chronic spontaneous urticaria (CSU). This applies to patients 12 and older who don't respond to standard antihistamines. It is the first targeted medicine for CSU approved in the EU in over 10 years. Dupixent continues to grow, with sales reaching €11.47 billion in the first nine months of 2025, a 22.7% increase. Despite the news, Sanofi stock is up only 1.9% year to date compared to the industry average of 16%.